Dashboard
1
The company has declared Positive results for the last 10 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 2,163.79 MM
- NET PROFIT(HY) At CNY 1,187.76 MM has Grown at 59.72%
- ROCE(HY) Highest at 34.9%
2
With ROE of 29.16%, it has a attractive valuation with a 7.88 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 54,018 Million (Large Cap)
18.00
NA
0.00%
-0.41
30.78%
6.98
Revenue and Profits:
Net Sales:
1,736 Million
(Quarterly Results - Jun 2026)
Net Profit:
905 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.45%
0%
24.45%
6 Months
21.76%
0%
21.76%
1 Year
29.73%
0%
29.73%
2 Years
142.66%
0%
142.66%
3 Years
407.18%
0%
407.18%
4 Years
504.88%
0%
504.88%
5 Years
322.56%
0%
322.56%
Shanghai Allist Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
173.97%
EBIT Growth (5y)
58.36%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.66
Tax Ratio
14.09%
Dividend Payout Ratio
20.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
39.07%
ROE (avg)
10.46%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
5.43
EV to EBIT
15.14
EV to EBITDA
14.95
EV to Capital Employed
8.48
EV to Sales
6.86
PEG Ratio
0.30
Dividend Yield
NA
ROCE (Latest)
56.00%
ROE (Latest)
30.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
1,736.00
1,583.80
9.61%
Operating Profit (PBDIT) excl Other Income
855.70
734.30
16.53%
Interest
0.00
0.00
Exceptional Items
7.80
7.00
11.43%
Consolidate Net Profit
904.70
636.00
42.25%
Operating Profit Margin (Excl OI)
485.30%
455.30%
3.00%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 9.61% vs 8.90% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 42.25% vs 10.94% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
5,123.80
3,516.00
45.73%
Operating Profit (PBDIT) excl Other Income
2,339.60
1,515.00
54.43%
Interest
0.20
0.10
100.00%
Exceptional Items
40.30
28.90
39.45%
Consolidate Net Profit
2,189.10
1,429.80
53.11%
Operating Profit Margin (Excl OI)
447.90%
419.60%
2.83%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 45.73% vs 76.54% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 53.11% vs 121.95% in Dec 2024
About Shanghai Allist Pharmaceuticals Co., Ltd. 
Shanghai Allist Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






